High-Value Edge
Single-stop Growth Accelerator for any vertical & horizontal, organic & inorganic growth goals
Why settle for 10% year-on-year growth when you can grow 10X in 2 years!
Sign up to grow a Higher Value of your business.
About us
WHAT WE DOHigh-Value Edge is a Growth partner for mid-size & semi-large companies looking for growth through M&A, partnerships, and capital raise. We have helped 20+ small and medium-sized companies grow at least 3X through organic marketing, branding & sales, and 10X through strategic partnerships, acquisitions, consolidation & capital-raising. This number will be doubled in the next 2 years, with the same number of businesses currently under our acceleration.
WHAT MAKES US DIFFERENTWhile there are a lot of accelerators today, for differentiated and early-stage start-ups, there aren’t any for stable and competitive mid-size companies. Our high-value acceleration model provides growth solutions to mid-segment and semi-large companies. In a cluttered and noisy market today, this is a genuine single-stop room for solving your specific business issues, with a clear focus, and credible global reach and partnerships with those who matter.
RECOGNITIONS
Awarded Best Value Creator at the Global StartUp & Entrepreneurship Conclave 2023
Emerging Strategy of the Year in the Business World Excellence Award 2020
Future of Workplace & Leadership Award 2019
Excellence in Change & Transformation at People and Culture Summit 2018
Great Place To Work – 2022, 2023 & 2024
High-Value Offerings
Sign up to grow a Higher Value of your business.
Private Market Investment Offering, for Equity Capital or M&A – Advisory & Execution
Before the deal
Business Model & Value assessment
Designing Value proposition
Financial & GTM Modeling & Projections
Deal structuring
Building Investment thesis & proposals
Market research
During the deal
Outreach on LinkedIn & Emails
Pitching & Pitch updating
Negotiating
After the deal
Organization Restructuring
Integration
Change Management
Training & Organization Development
Capital Solutions
CAPITAL
Private Offering
- Equity Capital (VC, PE, CVC)
Acquisition Debt
- LBO and D/E planningWorking Capital
- Project funding, Credit line, Spot factoring
GROWTHInorganic
- Buy/Sell assets
- Global partnerships
- Consolidation
- Business Model Innovation
- Restructuring
EXIT- Consolidate & Earn-out
- Next-generation transition
- Complete sell-off
Growth Solutions
Outsourced OPEX Activities
Just manage your Direct Costs. Outsource your OPEX to us.
Inclusions:
Email Outreach
WhatsApp Outreach
LinkedIn Sales Navigator
Outsourced CRM Desk
Social Media lead generation
Social Media Content Marketing
SEO Crawling
Performance Ad Marketing
Website Merchandising
Outsourced Recruiter
Starting from
Outsourced Corporate Development Activities
Opportunities don't arrive at a date you set. They come without an announcement. Work for them and stay ready every day.
Inclusions:
Monitoring & Evaluating systems & processes
Creating & Maintaining Data Room
Continuous outreach to private investors, lenders, family offices & investment bankers
Create, maintain, publish, & send out investor newsletters regularly
Create & regularly update the investment offerings, deal structure, value proposition, pitch deck, & books for investors
Internal diligence & cleansing
Regular valuing of the company
Negotiation as a service
Starting from
Outsourced Fractional Leadership
Hire C-suite leaders on a fractional or interim basis at a much lower budget and give your business the flexibility and scalability it needs.
Chief of Staff
Chief Growth Officer
Chief Business Officer
Chief Marketing Officer
Chief Financial Officer
Chief HR Officer
12 hours in a month
Can be split in 4-24 sessions of 30-180 minutes each
Starting from
Establishing departmental systems & procedures
Regular supervising, mentoring & training of staff
Setting team's KPIs and regularly monitoring them
Hiring, inducting & bonding of the team members
Negotiations with Vendors & authorities
Monitoring & Controlling departmental budget, P&L
Strategic direction and decision-making
Coaching and supporting the business head with critical strategic decisions
Starting from
Skill & Behavioral Training Programs
High-Stake Skills for all professionals
High-stake Multi-partite Negotiations
Sales-force Skilling & Mindset change
Implementation & Execution Skills
Alignment Workshops
Middle Management
Leadership Essentials for Middle Managers
Leading with Emotional Intelligence
Building High-Performance Teams
Managing Difficult Conversations
Agile Mindset for Managers
Coaching & Mentoring for Managers
Performance Management & Feedback
Conflicy Resolution & Workplace Mediation
Managing Change & Organizational Transformation
Senior Leadership
Visionary Leadership & Strategic Thinking
Transformational Leadership
Building & Sustaining a High-Performance Culture
Influencing & Negotiation for Senior Leaders
Leading Change in a Disruptive World
Authentic Leadership & Trust Building
Active Listening & Empathy in Leadership
Managing Change with Agility & Resilience
Starter Kit for Start-Ups
Inclusions:
Logo variants
Website
Social Media Pages with Starter Content
Business Cards
Letterheads
Delivery time: 2 weeks with maximum 2 iterations
Inclusions:
Market research
Competition Analysis
Business Modeling
GTM Strategy
Delivery time: 2 weeks with maximum 2 iterations
Start your Growth journey today
(c) Hival House Consulting Partners Pvt. Ltd. All rights reserved.
Payment Page
Outsourced OPEX Activities
PAYMENTS WITHIN INDIAPay annually INR 33,79,188
(effectively INR 2,81,599 /m)
& Save 30%Pay quarterly INR 9,67,797
(effectively INR 3,22,599 /m)
& Save 19%Pay per month INR 3,99,599
INTERNATIONAL PAYMENTSPay annually USD 47,988
(effectively USD 3,999)
& Save 33%Pay quarterly USD 13,497
(effectively USD 4,499)
& Save 25%Pay per month USD 5,999
Payment Page
Outsourced Corporate Development Activities
PAYMENTS WITHIN INDIAPay annually INR 15,55,188
(effectively INR 1,29,599 /m)
& Save 35%Pay quarterly INR 4,48,797
(effectively INR 1,49,599 /m)
& Save 25%Pay per month INR 1,99,599
INTERNATIONAL PAYMENTSPay annually USD 29,988
(effectively USD 2,499 /m)
& Save 50%Pay quarterly USD 10,497
(effectively USD 3,499 /m)
& Save 30%Pay per month USD 4,999
Payment Page
Outsourced Fractional Leadership
PAYMENTS IN INDIAPay annually INR 13,15,188
(effectively INR 1,09,599 /m)
& Save 39%Pay quarterly INR 3,88,797
(effectively INR 1,29,599 /m)
& Save 28%Pay per month INR 1,79,599
INTERNATIONAL PAYMENTSPay annually USD 29,988
(effectively USD 2,499 /m)
& Save 38%Pay quarterly USD 8,097
(effectively USD 2,699 /m)
& Save 33%Pay per month USD 3,999
Deal Board
Evaluated & Verified by High-Value Diligence experts
Pharmaceutical company
selling in India, Europe & Africa
needs $3.5M Equity Capital
for global expansion
Pharmaceutical company
selling in India, Turkey, Germany,
Italy, Pakistan, and Vietnam
needs $11.5M Equity Capital
Deeptech. Maritime mobility.
in Italy
needs $4.5M Equity Capital
Mid-market Private Equity Acquirer
in Texas, U.S.
needs $3M Equity Capital per SPV
to acquire portfolio companies
SAAS Player
Headquartered in Switzerland
operating across the world
needs $1M Equity Capital
Passenger Mobility / Electric Vehicle /
App-based Cabs Aggregator
in India
needs $1M Equity Capital
Sector
Private Equity Acquisition
(mid-market)
Location
Dallas, Texas, U.S.A.
Requirement
$3M Equity Capital per SPV
Exit returns4X+ MOIC100%+ IRR12X+ Exit Value360% ROEIn <24 months
Top viewEach stack Value
$30MFunds needed per SPV
$12M
Needed ForTo buy portfolio companies
& gain speed of roll-upsFund structure$6M Senior Debt,
$3M Mez Debt &
$3M Equity Capital
Exit optionsIn 18-24 months- Selling to a Strategic Buyer- Selling to a Financial Buyer- Selling to Management- Public Offering
OverviewBreaking away from the usual 2-and-20 fee structure, the firm specializes in a compressed roll-up strategy. It is looking to acquire, consolidate, roll up 5 businesses in a platform, and exit with >100% IRR in <2 years. With a huge deal funnel & continuous flow, it can roll up as many stacks as the flow of funds.
DifferentiationSuperfast appreciation
100%+ IRR in 2 years
No Management Fee (2&20)
Large & fast deal funnel
Team of Consolidation & Growth experts
Strong teamA globally spread team comprises highly credible experts from the best B-schools and with a minimum 10 and maximum 38 years of experience having carried out numerous similar deals and 9-figure exits all over the world.
Request for the full Investment Offering prospectus
Disclaimer:
This material is for informational purposes only and does not constitute an offer to sell, a recommendation to buy, or a solicitation to buy any securities. Past performance is not indicative of future results. All investments involve risk, including potential loss of principal. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions.
Sector
SAAS, Accounting Software Solutions
Location
HQ in Switzerland
Offices in UK, US, Hungary
Selling all over the world
Requirement
$1M Equity Capital
EBITDA PositiveAlready past the Inflection Point
Incorporated in
Q1 2018Started Revenue
Q2 2019Profitable since
Q3 2024
Enterprise Value
$28.3MRevenue ‘25
$8.5MEBITDA ‘25
$2.3M
Need funds for
40% - Product Innovation
30% - Sales & Mktg in US & EU
20% - Operational Growth
10% - Working Capital
Current Cap Table
57% Founder. 21% Co-founder
22% Friends & Family
OverviewLeading private markets software automating waterfalls & carry designed to adapt to different use cases and client types. Founded in 2018, it has been bootstrapped from the ground up, profitable & on the upside of the J-curve.
DifferentiationAutomation & AI-driven
Customizable
Built by private markets experts for private
markets experts.
Acquisition & StickinessEstablished Clients:
29 onboarded clients, including Deloitte, HarbourVest, Gen2, Starwood Capital, Mercer, & JTC.Funds under Administration: >4,500 funds currently using the software with the expectation to reach >6,000+ by end of 2025Strong Pipeline:
60 prospective clients expected over the next 18-24 months.
Revenue Concentration:
Top five clients generate 67% of net sales ($3M), demonstrating high-value engagements.
Request for the full Investment Offering prospectus
Disclaimer:
This material is for informational purposes only and does not constitute an offer to sell, a recommendation to buy, or a solicitation to buy any securities. Past performance is not indicative of future results. All investments involve risk, including potential loss of principal. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions.
Sector
Passenger Mobility / Electric Vehicle / App-based Cabs Aggregator
Location
India
Requirement
$1M Equity Capital
Currently at the Inflection Point
Incorporated in
Jun 2023Started Revenue
Jan 2024Break even expected from
June 2025
Enterprise Value
$9MLY Revenue
$2M
Need funds for
Expansion across IndiaCurrent Cap Table
80% Founders. 10% Angels
10% Seed investors
OverviewApp-based cab booking aggregator beating Uber/Ola with 150K+ less fuel used.As number of rides per user increases, there’s 527% growth in Cumulative Revenue against the base of CAC ($2.4)
Differentiation0% Cancellation & surcharge for riders.
Electric Cabs only.
Better returns for drivers.
B2B & B2C with same ops.
Attractive unit economics
Success facts4.9 Avg Customer rating across 25,000 ratings
60k+ Total rides. 2000+ Daily Rides. 250 Cabs
20k+ Registered user. 17+ B2B clients
55% MoM Growth in number of rides
<10% MoM Driver partner churn rate
28 Charging Hubs
Request for the full Investment Offering prospectus
Disclaimer:
This material is for informational purposes only and does not constitute an offer to sell, a recommendation to buy, or a solicitation to buy any securities. Past performance is not indicative of future results. All investments involve risk, including potential loss of principal. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions.
Sector
A Pharmaceutical company manufacturing respiratory products
Location
India
Requirement
$3.5 M Equity Capital
(15% dilution)
OverviewA fast-growing pharmaceutical company specializing in Sterile Liquid Parenterals and Respiratory Solutions using WHO-GMP-certified FFS technology (Form-Fill-Seal).Operating from a state-of-the-art facility in India, the company has a manufacturing capacity of 10 million ampoules per month, catering to both domestic and international markets.The company generates revenue through domestic and international sales, contract manufacturing for third-party brands, and private label production. With approvals in Sri Lanka and plans to expand into the Philippines, Ethiopia, and other African markets, it is strategically positioning itself in regulated, high-growth regions.To accelerate its global expansion, the company is diluting 15% equity, ensuring that all funds are exclusively used for business growth with no promoter withdrawal. Additionally, an IPO is planned within the next three years at a valuation of $46M, offering investors a potential 2X return on their investment.
Exit proposition
2X MOIC
100% ROE
26% IRR
IPO planned in 3 years
Current Cap Table
Completely Bootstrapped so far. No previous round.
Making Revenue since
2009-2010Profitable since
2010-11Enterprise Value
$23+MAssets Value
$3.5 M total. $1 M in expansion.
LY Revenue (2023-24)
$5.5 MLY EBITDA (2023-24)
$1 M (18%)YTD Revenue (2024-25)
$4.63 MYTD EBITDA (2024-25)
$0.83 M (18%)
Need funds for
International ExpansionAll investment proceeds will flow directly into the company, with no promoter withdrawal, demonstrating long-term commitment.
DifferentiationWhat sets the company apart is its strong global expansion strategy, targeting highly regulated markets such as Sri Lanka, the Philippines, and Africa, backed by international certifications. Its cost-efficient, automated production, combined with a diversified product portfolio, allows for high-margin exports, contract manufacturing, and private-label branding.
Request for the full Investment Offering prospectus
Disclaimer:
This material is for informational purposes only and does not constitute an offer to sell, a recommendation to buy, or a solicitation to buy any securities. Past performance is not indicative of future results. All investments involve risk, including potential loss of principal. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions.
Sector
A Pharmaceutical company
(in Product manufacturing)
Location
India
Requirement
$11.5 M Equity Capital
(20% dilution)
OverviewThe company specializes in phytochemical (plant-based API) manufacturing, supplying pharmaceuticals, cosmeceuticals, and nutraceuticals to domestic and international markets. In FY 2022, 75% of revenue came from India and 25% from exports, with Turkey contributing 90% of exports. Its key products include Thiocolchicoside (muscle relaxant) and Colchicine (anti-gout), with new launches like Hyoscine (gastro painkiller) already introduced to the market in FY 2022-23 and Tacrolimus (immunosuppressant) planned for FY 2025-26 first quarter.Today, with a strong domestic and international presence, 60% of its revenue comes from India, while 40% comes from exports, with established exports to Turkey, Germany, Italy, Pakistan, and Vietnam, with 40% of revenue from international markets. JP Morgan has 30% equity in the Turkish company that buys from them.The company benefits from high TECHNO COMMERCIAL entry barriers, a strong customer base, and a backward integration strategy through its Australian subsidiary, ensuring raw material stability. With a projected debt-equity ratio of 1.50-1.60, it is strategically expanding its product range and market presence to enhance profitability and reduce product concentration risks.
Exit proposition
2X MOIC
100% ROE
26% IRR
IPO planned in 3 years
Current Cap Table
Completely Bootstrapped so far. No previous round.
Making Revenue since
2009-2010Profitable since
2011-12Enterprise Value
Approximately $50-55 MAssets Value
4.6 M total
LY Revenue (2023-24)
$9.36 MLY EBITDA (2023-24)
$2.12 M (22.65%)YTD Revenue (2024-25)
$12.5 MYTD EBITDA (2024-25)
Expected to be higher than LY
Need funds for
- For new product expansion
- Capacity enhancement for existing products
- For approvals into newer markets
- Strengthen its distribution networkAll investment proceeds will flow directly into the company, with no promoter withdrawal, demonstrating long-term commitment.
DifferentiationWhat sets the company apart is its focus on high-entry-barrier products, leveraging cutting-edge fermentation technology, regulatory expertise, and a backward integration model. Through its Australian subsidiary, it ensures a stable supply of raw materials, reducing dependency on third parties. Additionally, its dedicated R&D investments enable continuous innovation and new product development, making it adaptable to market demands.It is highly scalable due to the growing global demand for plant-based APIs, its strong customer base, and its expansion into high-growth therapeutic segments. With new product launches like Hyoscine (gastro painkiller) and Tacrolimus (immunosuppressant) in FY 2024, alongside increasing R&D capabilities, the company is well-positioned for long-term growth and global market leadership in niche fermentation-based APIs with applications in anti-inflammatory, anti-cancer, anti-hypertension, and pain management drugs.
Request for the full Investment Offering prospectus
Disclaimer:
This material is for informational purposes only and does not constitute an offer to sell, a recommendation to buy, or a solicitation to buy any securities. Past performance is not indicative of future results. All investments involve risk, including potential loss of principal. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions.